Lipoteichoic acid may affect the pathogenesis of bile duct damage in primary biliary cirrhosis

Autoimmunity. 2006 Mar;39(2):129-35. doi: 10.1080/08916930600623841.

Abstract

Aim: Intrahepatic bile ducts are the targets for inflammation in primary biliary cirrhosis (PBC), but their pathogenesis is not known. Gram-positive bacterial DNA was detected recently in gallbladder bile of PBC patients. In the present study, we assessed the possible pathological role of lipoteichoic acid (LTA), the gram-positive bacterial cell wall component, in PBC.

Methods: Liver samples, obtained from 20 patients with PBC (stage 1-2 with CNSDC: stage 3-4 with loss of bile ducts = 10:10) and from 13 patients with chronic hepatitis due to hepatitis C virus (CH-C) with lymphocytic cholangitis, were subjected to immunohistochemical staining with polyclonal rabbit anti-LTA as the primary antibody. Serum reactivities to LTA were studied by ELISA. After 1 microg of purified LTA was placed in a 96-well microplate as an antigen, an antibody capture assay was carried out using serum samples from PBC (n = 20), CH-C (n = 13) and healthy subjects (n = 11).

Results: LTA was localized around the sites of chronic non-suppurative destructive cholangitis (CNSDC) in the portal area in stage 1-2 PBC but was not detected in the portal area in CH-C. In stage 3-4 PBC, LTA was localized around sites of ductular proliferation at the periphery of portal tracts. IgM class anti-LTA serum titers were significantly higher in PBC than in CH-C. IgA class anti-LTA serum titers were significantly higher in PBC than in healthy subjects.

Conclusions: In the PBC livers, the profile of immunoreactivity to LTA changed markedly as the disease progressed. Sera from PBC showed higher levels of anti-LTA titers than CH-C (IgM) or from healthy subjects (IgA). The LTA-mediated immune system might affect the initiation and/or progression of PBC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antibodies, Bacterial / blood
  • Bile Ducts, Intrahepatic / drug effects
  • Bile Ducts, Intrahepatic / metabolism
  • Bile Ducts, Intrahepatic / microbiology
  • Bile Ducts, Intrahepatic / pathology
  • Female
  • Gram-Positive Bacteria / immunology
  • Gram-Positive Bacteria / pathogenicity
  • Hepatitis C, Chronic / etiology
  • Hepatitis C, Chronic / immunology
  • Hepatitis C, Chronic / microbiology
  • Hepatitis C, Chronic / pathology
  • Humans
  • Lipopolysaccharides / immunology*
  • Lipopolysaccharides / metabolism
  • Liver Cirrhosis, Biliary / etiology*
  • Liver Cirrhosis, Biliary / immunology
  • Liver Cirrhosis, Biliary / microbiology
  • Liver Cirrhosis, Biliary / pathology
  • Middle Aged
  • Teichoic Acids / immunology*
  • Teichoic Acids / metabolism

Substances

  • Antibodies, Bacterial
  • Lipopolysaccharides
  • Teichoic Acids
  • lipoteichoic acid